Navigation Links
Stemedica Enters into a Global Distribution Agreement with Life Technologies
Date:6/13/2013

San Diego, CA (PRWEB) June 13, 2013

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today they have entered into a Global Distribution Agreement with Life Technologies Corporation. Under the terms of this agreement, Life Technologies will exclusively offer Stemedica’s ischemic tolerant allogeneic adult mesenchymal stem cells (itMSCs) and neural stem cells (itNSCs) for sale worldwide to research, academic institutions and corporations both in the United States and internationally. Stemedica stem cell lines will be sold under the brand name Gibco® and will be available to purchase for research initiatives beginning Q2, 2013. The label will also carry the name of Stemedica as the manufacturer of the cell lines.

Life Technologies is a global biotechnology company with customers in more than 180 countries, providing more than 50,000 end-to-end solutions for customers in the fields of scientific research, genetic analysis and applied sciences. The Company’s systems, reagents and consumables represent some of the most cited brands in scientific research. Life Technologies employs approximately 10,000 people and upholds its ongoing commitment to innovation with more than 5,000 patents and exclusive licenses. The Company had sales of $3.8 billion in 2012.

“We are honored to be associated with a company of the caliber of Life Technologies.” stated Maynard Howe, PhD, CEO and Vice Chairman of Stemedica. “The goal of our collaboration is to serve the worldwide market of corporate research and academic institutions. Providing multiple stem cell products using a patented large-scale Reduced Oxygen Tension manufacturing process (Patent #8,420,394) to scientists who are conducting or plan to conduct stem cell research will accelerate new discoveries and ultimately enable physicians to treat medical conditions and diseases for which there are no effective treatments.”

According to Nikolai Tankovich, MD, PhD, President and Chief Medical Officer of Stemedica, “This collaboration between Stemedica and Life Technologies creates a unique opportunity for all researchers and scientists around the world to advance their discoveries. This acceleration is possible because Stemedica’s stem cell products are manufactured under controlled cGMP conditions allowing for uniform reproducibly manufactured cells to support controlled research.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarct, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information, please contact Dave McGuigan at dmcguigan (at) stemedica (dot com).

Read the full story at http://www.prweb.com/releases/stemedica-itmsc-itnsc/life-technologies/prweb10829195.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
2. Stemedica Forms Cardiology Division. Sergey Sikora, PhD Appointed As Division President
3. Noted Cardiologist Robert Wilensky to Join Stemedica Cardiology Division Scientific & Medical Advisory Board
4. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
5. Higher medical home performance rating of community health centers linked with higher operating cost
6. Feinstein Institute to Receive Grant from Centers for Medicare & Medicaid Services to Improve Schizophrenia Treatment
7. Innokin Leo Pro Enters Russia E Cigarette Market
8. Rising Solar Engineering and Design Firm Enters 1.7 MW's in Connecticut ZREC Auction and Positions for Future Growth
9. GSA welcomes National Hartford Centers of Gerontological Nursing Excellence
10. Community health centers compare well with private practices, Stanford researcher finds
11. Allergies May Plague Renters More Than Homeowners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Peyman Ghasri, skin doctor ... variety of comprehensive procedures for facial enhancement. The treatments now available at Castle ... and nasal reshaping. , As a result, patients can improve virtually every ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
(Date:2/10/2016)... Beach, Florida (PRWEB) , ... February 10, 2016 ... ... Country Club) announced that it has been awarded the prestigious Distinguished Emerald Club ... World award program conducted by BoardRoom magazine, one of the most respected trade ...
(Date:2/10/2016)... Petaluma, CA (PRWEB) , ... February 10, 2016 , ... ... newest and most versatile series of monitor mounts ever. , “Our goal was ... flexible and easy to install system that we have ever created.” said Darren Hulsey, ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
(Date:2/10/2016)... Association, in partnership with ALS Finding a Cure, is pleased ... track TDP43 aggregation. The successful team(s) with the most developed ... --> --> ALS is ... brain and the spinal cord. Eventually, people with ALS lose ... leads to total paralysis and death within two to five ...
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
Breaking Medicine Technology: